Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis

Abstract

Monoclonal antibodies and small molecule tyrosine kinase inhibitors (TKIs) directed against the vascular endothelial growth factor (VEGF) or its receptors have been investigated in several studies for the treatment of advanced gastric cancer (GC). In the present study, we aimed to evaluate the efficacy and safety of angiogenesis inhibitors in advanced GC. We searched published randomized controlled trials (RCTs) comparing angiogenesis inhibitors with non-angiogenesis inhibitors for the treatment of GC. MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched. The extracted data on progression-free survival (PFS) and overall survival (OS) were measured in terms of hazard ratios (HR) and corresponding 95 % confidence intervals (CIs). In addition, risk ratios (RR) and corresponding 95 % CIs were pooled for objective response rate (ORR), disease control rate (DCR), and risk of adverse events (AEs). Ten RCTs involving 2786 patients were included. Compared with non-angiogenesis inhibitor-containing regimens, angiogenesis inhibitor-containing regimens resulted in a significant improvement in OS (HR 0.80, 95 % CI 0.69–0.93, P = 0.004), prolonged PFS (HR 0.66, 95 % CI 0.51–0.86, P = 0.002), and superior ORR (RR 1.34, 95 % CI 1.09–1.65, P = 0.005) and DCR (RR 1.37, 95 % CI 1.17–1.61, P = 0.0001). Angiogenesis inhibitors were associated with a greater number of AEs, but most of these were predictable and manageable. However, hand-foot syndrome, diarrhea, and gastrointestinal (GI) perforation were significantly increased in patients treated with angiogenesis inhibitors. In summary, angiogenesis inhibitor-containing regimens were superior to non-angiogenesis inhibitor-containing regimens in terms of OS, PFS, RR, and DCR in patients with advanced GC.Electronic supplementary materialThe online version of this article (doi:10.1186/s13045-016-0340-8) contains supplementary material, which is available to authorized users.

Plasma cytokeratin‐18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib

“…Antiangiogenic TKIs such as those inhibiting vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) appear to have a higher reported incidence of diarrhea in the human literature compared with nonangiogenic TKIs . This might suggest a possible relationship between angiogenic signaling inhibition and the development of diarrhea .…”

Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases

“…For instance, targeting the VEGF pathway in gastric cancers has gained increasing attention after the results obtained in phase III clinical trials, which demonstrate superior survival outcome with some anti-angiogenic drugs, such as ramucirumab, apatinib, and bevacizumab, than with the standard therapy [38]. Nevertheless, further studies are required to deeply explore the timing and potentially predictive biomarkers of angiogenesis inhibitors to improve the selection of patients and improve clinical benefit.…”

Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study

“…However, except for ramucirumab, most of these antiangiogenic agents failed to improve the patients' survival condition [12,13]. Recently in 2014, apatinib, a kind of selective vascular endothelial growth factor receptor-(VEGFR-) 2 inhibitor, has been approved and showed good treatment efficacy for advanced gastric cancer [14].…”